U.K. orthopedics giant Smith & Nephew has been riding its checkbook into emerging markets all year, and now the company has signed a deal to pick up a share of its Brazilian wound care partner with an eye on vertical integration.
Brazil's rapidly growing drug market, fueled by an aggressive government plan to boost healthcare spending, is spurring new production facilities, but not just from the Western drugmakers. Russia's Biocad is building a new $40 million facility to make biosimilars after having struck a partnership with a Brazilian drugmaker to produce a copy of a top cancer drug.
Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
Catalent is moving further and faster with its global expansion plans while building its softgel and nutritional product capacity. The contract manufacturer will move into Brazil with the acquisition of Relthy Laboratórios.
California's Ariosa Diagnostics is hitting Brazil with its prenatal test that screens for conditions such as Down syndrome, a bet that the country's massive annual birth rate offers a path to major market growth.
Teva Pharmaceutical Industries CEO Jeremy Levin figures Brazil and China, among the fastest-growing pharmaceutical markets in the world, offer plenty of opportunity for the generics giant to build its drug portfolio.
GE Healthcare has bought Brazil's Omnimed, a producer of patient monitoring devices, part of the conglomerate's effort to increase its share of the Latin American market.
Brazilian drugmaker Hypermarcas shows that market savvy pays, even when an economy hits the skids. Despite an unexpected lag in GDP growth, Hypermarcas posted a surprise profit for the second quarter. A sales surge helped swing the company into the black, with pharma sales alone up 13.3%.
Because Sanofi has been investing heavily in emerging markets in recent years to help it offset revenue declines from patent expirations, a 2.3% crash in sales in those markets was a big surprise.
Western drugmakers headed into the BRIC countries to provide the kind of volume growth they couldn't scare up elsewhere. But it is not turning out exactly as planned. India has expanded price controls.